Ken Griffin Zentalis Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.9 - $4.57 $39,440 - $62,152	-13,600 Reduced 40.84%	19,700 $72,000
Q2 2024 Aug 14, 2024	BUY	$4.09 - $16.13 $32,311 - $127,426	7,900 Added 31.1%	33,300 $136,000
Q1 2024 May 15, 2024	SELL	$10.83 - $16.49 $338,979 - $516,136	-31,300 Reduced 55.2%	25,400 $400,000
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $436,896 - $893,772	44,400 Added 360.98%	56,700 $859,000
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $37,297 - $53,751	-1,900 Reduced 13.38%	12,300 $246,000
Q2 2023 Aug 14, 2023	SELL	$17.41 - $30.05 $1,741 - $3,005	-100 Reduced 0.7%	14,200 $400,000
Q1 2023 May 15, 2023	SELL	$16.14 - $24.94 $171,084 - $264,364	-10,600 Reduced 42.57%	14,300 $245,000
Q4 2022 Feb 14, 2023	SELL	$18.07 - $25.6 $475,241 - $673,280	-26,300 Reduced 51.37%	24,900 $501,000
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $629,153 - $986,803	31,100 Added 154.73%	51,200 $1.11 Million

142

68M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $198M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.